Clinical trials: Monoclonal Antibody
HTLV-1
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- Trial name
- NCT00076843
- Testing
- Hu MiK-Beta-1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Non-curable Patients With SCCHN
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
- Trial name
- NCT00542308
- Testing
- Zalutumumab
- Where
- 48 sites in United States, Austria and 9 more
- Volunteers
- 90 people
- Sponsor
- Genmab
Arthritis, Rheumatoid
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active…
- Trial name
- NCT00718718
- Testing
- CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg
- Where
- 38 sites in United States, Hungary and 5 more
- Volunteers
- 187 people
- Sponsor
- Centocor, Inc.
RSV Immunization
Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China
The goal of this clinical trial is to evaluate whether an AI-assisted primary care intervention for parents can increase RSV monoclonal antibody (mAb) uptake among infants, and to assess the cost-effectiveness and potential for…
- Trial name
- NCT07856290
- Testing
- RSV AI-assisted primary care intervention
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Fudan University
Unspecified Adult Solid Tumor, Protocol Specific
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002482
- Testing
- antibody therapy, biological therapy, muromonab-CD3
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Adenocarcinoma
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
The primary objectives of this study were to assess the safety and tolerability of intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of…
- Trial name
- NCT02204046
- Testing
- BIWA 4
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Episodic Migraine, Chronic Migraine
CGRP Inhibition, Autonomic Function, and Migraine
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e.
- Trial name
- CGRP-1 (NCT04628429)
- Testing
- Erenumab, Galcanezumab, Fremanezumab
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Urothelial Carcinoma, Advanced Cancer
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
- Trial name
- NCT03507166
- Testing
- RC48-ADC
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- RemeGen Co., Ltd.
Arthritis, Rheumatoid
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent…
- Trial name
- NCT00299546
- Testing
- Golimumab 50 mg, Golimumab 100 mg
- Where
- 77 sites in United States, Australia and 8 more
- Volunteers
- 461 people
- Sponsor
- Centocor, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00052403
- Testing
- monoclonal antibody anti-anb3 integrin, anti-cytokine therapy, antiangiogenesis therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumor
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
This is a phase Ia, single-center, open label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor efficacy of MW11 (a recombinant humanized anti-PD-1 monoclonal…
- Trial name
- NCT04478461
- Testing
- PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Sickle Cell Disease
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain…
- Trial name
- SUSTAIN (NCT01895361)
- Testing
- SelG1
- Where
- 56 sites in United States, Brazil and 1 more
- Volunteers
- 198 people
- Sponsor
- Reprixys Pharmaceutical Corporation
Lymphoma
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003963
- Testing
- rituximab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Crohn's Disease
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
This study will assess the safety and efficacy of QAX576 if patients with fistulizing Crohn's disease.
- Trial name
- NCT01355614
- Testing
- QAX576, Infliximab
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Nephrotic Syndrome
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
The goal of this clinical trial is to learn whether adding Zuberitamab to standard corticosteroid therapy can help prevent relapse in children and adolescents aged 1 to 18 years with newly diagnosed steroid-sensitive nephrotic…
- Trial name
- NCT07765914
- Testing
- Zuberitamab, standard corticosteroid treatment
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- Children's Hospital of Fudan University
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Advanced Solid Tumours
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed…
- Trial name
- NCT01058538
- Testing
- L19IL2
- Where
- 2 sites in Germany, Italy
- Volunteers
- 33 people
- Sponsor
- Philogen S.p.A.
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
- Trial name
- NCT02006485
- Testing
- Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib, Ublituximab + TGR-1202 + bendamustine
- Where
- 6 sites in United States
- Volunteers
- 160 people
- Sponsor
- TG Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.